References
- Ziepert M, Hasenclever D, Kuhnt E, . Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
- Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
- Blay J, Gomez F, Sebban C, . The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562–3568.
- Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 2008;46: 213–223, vii.
- Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):110–112.
- Elis A, Blickstein D, Klein O, . Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 2002;69:41–44.
- Weeks JC, Yeap BY, Canellos GP, . Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196–1203.
- Porrata LF, Rsitow K, Inwards DJ, . Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010;24:1343–1349.
- Guglielmi C, Gomez F, Philip T, . Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16:3264–3269.
- Aviles A, Narvaez BR, Diaz-Maqueo JC, . Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma. Leuk Lymphoma 1993;9:377–380.
- Wakao D, Murohashi I, Tominaga K, . Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Ann Hematol 2002;81:140–146.